AI Image
Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
AZ Family • • business
Key Points:
- Hundreds of lawsuits have been filed against GLP-1 drugmakers Eli Lilly and Novo Nordisk, accusing their weight-loss medications of causing permanent eye damage and vision loss, specifically non-arteritic anterior ischemic optic neuropathy (NAION).
- NAION, which causes sudden vision loss due to reduced blood flow to the optic nerve, is not currently listed as a side effect on U.S. drug labels but appears on some international labels.
- The lawsuits claim the companies failed to warn patients about the risk of NAION linked to drugs like semaglutide, tirzepatide, and dulaglutide, sold under brand names including Ozempic, Wegovy, Zepbound, Mounjaro, and Trulicity.
- Legal representatives report a recent surge in vision loss claims, highlighting cases where patients experienced rapid and severe vision deterioration after using these medications.
- Both Eli Lilly and Novo Nordisk deny a significant connection between their drugs and vision loss, emphasizing their commitment to patient safety and actively contesting the lawsuits.
